Close Menu

NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved Amoy Diagnostics' SuperARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs, the company said today.

According to Xiamen, China-based AmoyDx, the real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples from patients with advanced or metastatic NSCLC. The test was CE-IVD marked in April.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr
17
Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.